Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028327 · ClinicalTrials.gov registry record · Phase 3
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT00028327 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 250 participants.
The verdict
NCT00028327, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
Many HIV infected patients admitted to the intensive care area (ICA) have never taken anti-HIV drugs. The purpose of this study is to learn whether starting anti-HIV drugs while patients are in an ICA will help them to survive and get better faster. This study will also evaluate patients who, though not in an ICA, have been admitted to the hospital for serious illnesses or infections.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Nelfinavir mesylate
- DRUG Lamivudine/Zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028327
The ClinicalTrials.gov registry entry for NCT00028327 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zidovudine is the first listed.
NCT00028327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028327 about?
NCT00028327 is a clinical study titled "Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care". Many HIV infected patients admitted to the intensive care area (ICA) have never taken anti-HIV drugs. The purpose of this study is to learn whether starting anti-HIV drugs while patients are in an ICA will help them to survive and get better faster. This study will also evaluate patients who, though...
What is the current status of trial NCT00028327?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants.
What interventions are being tested in trial NCT00028327?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Efavirenz (DRUG), Nelfinavir mesylate (DRUG), Lamivudine/Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00028327?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.